Evidence map›Paper›PMID 32038611›Full record

ArticleFrontiers in immunology2019

Detection of EXP1-Specific CD4+ T Cell Responses Directed Against a Broad Range of Epitopes Including Two Promiscuous MHC Class II Binders During Acute

Janna Heide, Nils H Wildner, Christin Ackermann, Melanie Wittner, Matthias Marget, Alessandro Sette, John Sidney, Thomas Jacobs, Julian Schulze Zur Wiesch

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.7field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Epitope mapping ofHeliyon · 2023
    Article
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 2 countries.

Janna HeideInfectious Diseases Unit, I. Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Nils H WildnerInfectious Diseases Unit, I. Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Christin AckermannInfectious Diseases Unit, I. Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Melanie WittnerInfectious Diseases Unit, I. Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Matthias MargetDepartment of Transfusion Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
Alessandro SetteDivision of Vaccine Discovery, La Jolla Institute for Immunology, La Jolla, CA, United States.
John SidneyDivision of Vaccine Discovery, La Jolla Institute for Immunology, La Jolla, CA, United States.
Thomas JacobsProtozoa Immunology, Bernhard-Nocht-Institute for Tropical Medicine, Hamburg, Germany.
Julian Schulze Zur WieschInfectious Diseases Unit, I. Department of Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
German Center for Infection Research · DELa Jolla Institute for Immunology · USUniversität Hamburg · DEBernhard Nocht Institute for Tropical Medicine · DEUniversity Medical Center Hamburg-Eppendorf · DE

Funding

Development of a pipeline tool to predict immunogenicity of cancer neo-epitopesR21AI134127 · NIAID · LA JOLLA INSTITUTE FOR IMMUNOLOGY · PI PETERS, BJOERN, SETTE, ALESSANDRO · 2018 to 2019
$495k
NIAID NIH HHS R21 AI134127
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AdolescentAdultAgedAmino Acid SequenceAntigens, ProtozoanCD4-Positive T-LymphocytesEnzyme-Linked Immunospot AssayEpitope MappingEpitopes, T-LymphocyteFemaleHistocompatibility Antigens Class IIHost-Parasite InteractionsHumansImmunophenotypingMalaria, FalciparumMaleAntigens, ProtozoanEpitopes, T-LymphocyteHistocompatibility Antigens Class IIPeptidesQF116 antigen, Plasmodium falciparumCD4+CD8+HLA bindingHLA class IImalariaPlasmodium falciparumPlasmodium vivaxT cell epitope

Identifiers

PMID32038611
PMCPMC6993587
OpenAlexW3002159853

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.